INKT MINK THERAPEUTICS INC

MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update

MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update

Conference Call on Thursday, November 3rd, 2022, at 8:30 a.m. ET

NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced it will release its third quarter 2022 financial results before the market opens on Thursday, November 3rd, 2022. MiNK leadership will host a conference call and webcast at 8:30 a.m. ET that same day.

Conference Call:

Dial-in numbers: 646-307-1952 (United States); 888-672-2415 (USA & Canada)

Event ID: 3583551

Webcast:

A webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at and via

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit .

Contact

Kimberly Ha

KKH Advisors

917-291-5744



EN
20/10/2022

Underlying

INKTMINK THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MINK THERAPEUTICS INC

 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Conte...

MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, has been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 11-1...

11h / 21m 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Announces Abstract Acceptance for Presentation at th...

MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, has been accepted for presentation at the ATS International Conference 2026 occurring May 15-20, 2026 in Orl...

April 1, 2026 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Progr...

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 patients annually in US/EUC-Further Consortium collaboration adds to growing non-dilutive funding for PRAME-TCR iNKT in pediatric oncologyNIH STTR grant and Mary Gooze philanthropic award fully fund graft-versus-host disease (GVHD) preclinical data with clinical trial launch in 1H 2026Keystone Symposia data report iNKT depletion in end-stage Pulmonary ...

March 31, 2026 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financia...

MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potential NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report fi...

March 17, 2026 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Announces Collaboration with C-Further to Advance PR...

MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers Selected as a C-Further program with up to ~$1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial revenue participation NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT) a clinical-stage biopharmaceutical company advancing invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases, today announced a strategic colla...

March 10, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch